PMID- 33124165
OWN - NLM
STAT- MEDLINE
DCOM- 20210511
LR  - 20210511
IS  - 1742-1241 (Electronic)
IS  - 1368-5031 (Linking)
VI  - 75
IP  - 3
DP  - 2021 Mar
TI  - Association between thiazolidinedione use and rheumatoid arthritis risk in 
      patients with type II diabetes, a population-based, case-control study.
PG  - e13804
LID - 10.1111/ijcp.13804 [doi]
AB  - AIM: A previous study revealed that PPARgamma agonists have anti-inflammatory effects 
      in rheumatoid arthritis (RA). Furthermore, some studies have shown that type 2 
      diabetes mellitus (T2DM) may elicit the development of RA. In this study, we 
      aimed to investigate whether the use of thiazolidinediones (TZDs) is associated 
      with a lower risk of developing RA in patients with T2DM. METHODS: Based on the 
      Taiwan National Health Insurance Research Database, we conducted a nationwide 
      case-control study. The selected cases were patients with T2DM who were diagnosed 
      with RA between 2000 and 2013. The controls were retrieved at a ratio of 1:4 by 
      propensity score matching. Logistic regression was conducted to evaluate whether 
      TZD use lowers the risk of RA in patients with T2DM. The dose-response effect was 
      examined according to the total TZD dose, within 2 years before the index date 
      (the first diagnosis date of RA), and TZD doses were divided into four groups by 
      cumulative Defined Daily Dose (cDDD): <30, 31-90, 91-365, and >365 cDDDs. 
      RESULTS: A total of 3605 cases and 14 420 controls were included in this study. 
      After adjusting for age, sex, baseline comorbidities, the results demonstrated 
      that TZD use did not significantly reduce the risk of RA in patients with T2DM 
      (adjusted OR = 0.91, 95% CI 0.81-1.02). In the subgroup analysis by total TZD 
      exposure dose within 2 years, 91-365 cDDDs of TZD had a lower risk of RA 
      development, aOR = 0.87 (95% CI 0.71-1.06) and >365 cDDDs of TZD, aOR = 0.85 (95% 
      CI 0.73-1.01). In the trend test, P was <.05. CONCLUSIONS: TZD use might reduce 
      the risk of RA in patients with T2DM, but it was non-statistically significant. 
      Further research is necessary to assess this association.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Hsieh, Ming-Shun
AU  - Hsieh MS
AUID- ORCID: 0000-0003-2734-392X
AD  - Department of Emergency Medicine, Taipei Veterans General Hospital, Taoyuan 
      Branch, Taoyuan, Taiwan.
AD  - Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei, 
      Taiwan.
AD  - School of Medicine, National Yang-Ming University, Taipei, Taiwan.
FAU - Hung, Pin-Shun
AU  - Hung PS
AD  - Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei, 
      Taiwan.
FAU - Hsieh, Vivian Chia-Rong
AU  - Hsieh VC
AD  - Department of Health Services Administration, China Medical University, Taichung, 
      Taiwan.
FAU - Liao, Shu-Hui
AU  - Liao SH
AD  - Department of Pathology and Laboratory, Taipei Veterans General Hospital, Taoyuan 
      Branch, Taoyuan, Taiwan.
FAU - How, Chorng-Kuang
AU  - How CK
AUID- ORCID: 0000-0002-7419-0797
AD  - Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei, 
      Taiwan.
AD  - School of Medicine, National Yang-Ming University, Taipei, Taiwan.
AD  - Kinmen Hospital, Ministry of Health and Welfare, Kinmen, Taiwan.
LA  - eng
GR  - MOHW107-TDU-B-212-123004/Ministry of Health and Welfare, Taiwan/
GR  - DMR-107-192/China Medical University Hospital/
GR  - BM10701010021/Academia Sinica Stroke Biosignature Project/
GR  - MOST106-2321-B-039-005/MOST Clinical/
GR  - MOST106-2321-B-039-005/Trial Consortium for Stroke/
GR  - Tseng-Lien Lin Foundation, Taichung, Taiwan/
GR  - Katsuzo and Kiyo Aoshima Memorial Funds, Japan/
PT  - Journal Article
DEP - 20201109
PL  - India
TA  - Int J Clin Pract
JT  - International journal of clinical practice
JID - 9712381
RN  - 0 (Thiazolidinediones)
SB  - IM
MH  - *Arthritis, Rheumatoid/complications/drug therapy/epidemiology
MH  - Case-Control Studies
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - Humans
MH  - Retrospective Studies
MH  - Taiwan/epidemiology
MH  - *Thiazolidinediones/therapeutic use
EDAT- 2020/10/31 06:00
MHDA- 2021/05/12 06:00
CRDT- 2020/10/30 06:01
PHST- 2020/07/11 00:00 [received]
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/10/31 06:00 [pubmed]
PHST- 2021/05/12 06:00 [medline]
PHST- 2020/10/30 06:01 [entrez]
AID - 10.1111/ijcp.13804 [doi]
PST - ppublish
SO  - Int J Clin Pract. 2021 Mar;75(3):e13804. doi: 10.1111/ijcp.13804. Epub 2020 Nov 
      9.